Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE:002773)

SHE:002773 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	3,828	5,690	4,702	3,585	2,939	3,328
Trading Asset Securities	2,565	-	-	100	200	-
Cash & Short-Term Investments	6,393	5,690	4,702	3,685	3,139	3,328
Cash Growth	15.29%	21.00%	27.59%	17.41%	-5.67%	45.71%
Accounts Receivable	166.93	177.85	160.41	160.69	204.63	346.2
Other Receivables	8.98	23.04	28.81	27.88	43.59	25.57
Receivables	175.9	200.89	189.22	188.57	248.22	371.77
Inventory	386.24	386.86	403.61	330.96	295.62	239.64
Other Current Assets	67.93	11.56	10.63	24.22	15.89	22.77
Total Current Assets	7,023	6,289	5,306	4,229	3,699	3,962
Property, Plant & Equipment	2,261	2,353	2,411	2,553	2,097	1,781
Long-Term Investments	15.97	16.44	16.78	16.98	17.73	18.35
Goodwill	-	-	-	-	-	214.84
Other Intangible Assets	363.12	286.89	316.8	331.14	278.21	294.16
Long-Term Deferred Tax Assets	136.31	259.46	358.08	486.31	545.66	430.01
Long-Term Deferred Charges	37.28	123.24	99.33	70.47	84.67	55.56
Other Long-Term Assets	33.48	14.48	22.01	33.93	233.89	245.29
Total Assets	9,870	9,342	8,530	7,721	6,956	7,001
Accounts Payable	208.57	297.16	344.03	409.54	343.13	288.87
Accrued Expenses	27.11	233.88	203.64	169.59	174.63	193.52
Current Portion of Leases	1.47	1.73	0.53	1.6	2.57	-
Current Income Taxes Payable	65.39	13.31	9.82	19.69	16.49	37.45
Current Unearned Revenue	5.36	8.92	5.1	9.14	8.39	11.84
Other Current Liabilities	370.29	99.98	91.31	84.1	122.16	448.02
Total Current Liabilities	678.19	654.99	654.43	693.66	667.37	979.7
Long-Term Leases	2.2	3.47	1.48	3.27	4.43	-
Long-Term Unearned Revenue	29.12	23.58	22.94	30.3	25.51	51.4
Long-Term Deferred Tax Liabilities	10.47	13.03	7.94	5.14	2.06	2.37
Other Long-Term Liabilities	-	-	30.96	81.48	151.71	211.88
Total Liabilities	719.98	695.07	717.76	813.85	851.08	1,245
Common Stock	921.32	919.78	919.46	919.46	919.46	919.46
Additional Paid-In Capital	2,028	1,997	1,990	1,994	1,986	1,981
Retained Earnings	6,218	5,738	4,896	3,989	3,185	2,856
Comprehensive Income & Other	-1.65	-1.33	-1.34	-1.05	-0.83	-0.4
Total Common Equity	9,166	8,653	7,804	6,902	6,090	5,756
Minority Interest	-16.31	-6.34	7.89	5.07	15.24	-
Shareholders' Equity	9,150	8,647	7,812	6,907	6,105	5,756
Total Liabilities & Equity	9,870	9,342	8,530	7,721	6,956	7,001
Total Debt	3.68	5.2	2.01	4.87	7	-
Net Cash (Debt)	6,389	5,684	4,700	3,681	3,132	3,328
Net Cash Growth	15.36%	20.94%	27.70%	17.52%	-5.88%	45.72%
Net Cash Per Share	6.95	6.20	5.13	4.02	3.42	3.82
Filing Date Shares Outstanding	921.32	919.78	919.46	919.46	919.46	919.46
Total Common Shares Outstanding	921.32	919.78	919.46	919.46	919.46	919.46
Working Capital	6,345	5,634	4,651	3,535	3,031	2,982
Book Value Per Share	9.95	9.41	8.49	7.51	6.62	6.26
Tangible Book Value	8,803	8,366	7,487	6,571	5,812	5,247
Tangible Book Value Per Share	9.56	9.10	8.14	7.15	6.32	5.71
Buildings	-	2,126	1,989	1,785	1,137	-
Machinery	-	1,271	1,236	1,088	830.91	-
Construction In Progress	-	112.35	166.54	475.88	808.69	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.